Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting

View original at globenewswire.com
Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting Ghent, BELGIUM, March 24, 2026 (GLOBE NEWSWIRE) -- Press release – regulated information Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solution…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company will require additional funds beyond May 2026 to meet its capital and expenditure needs and ensure its going concern even if the intended restructuring would be completed

    60% confidence

  • The company currently believes that the updated timeline will allow sufficient time to progress financing discussions, ensuring that the annual report and financial figures correctly reflect a more advanced status thereof

    60% confidence

  • Financing might eventually not be available or if available, might result in an important dilution of existing shareholders or not be available on commercially favourable terms

    60% confidence

  • No binding financing proposals are yet obtained

    60% confidence

  • The updated timeline will allow sufficient time to progress financing discussions, ensuring that the annual report and financial figures correctly reflect a more advanced status thereof

    60% confidence

  • No binding financing proposals are yet obtained

    60% confidence

  • No binding financing options or proposals are obtained by the company as of March 24, 2026

    60% confidence

  • Biotalys confirms it is in ongoing discussions with existing and new investors to obtain additional financing to support its operations in going concern

    60% confidence

  • The company has a cash runway until end of May 2026

    60% confidence

  • The company will require additional funds beyond May 2026 to meet its capital and expenditure needs and ensure its going concern even if the intended restructuring of the company would be completed

    60% confidence

  • Such financing might eventually not be available or if available, might result in an important dilution of existing shareholders or, in general, not be available on commercially favourable terms

    60% confidence

  • The company has a cash runway until end of May 2026

    60% confidence

  • Biotalys does not have sufficient working capital to cover the working capital needs for a period of at least 12 months

    60% confidence

  • The company is in ongoing discussions with existing and new investors to obtain additional financing to support its operations in going concern

    60% confidence

  • Biotalys does not have sufficient working capital to cover the working capital needs for a period of at least 12 months as of the date hereof and only has a cash runway until end of May 2026

    60% confidence

Cited in these Via News reports